European Archives - Page 126 of 1345 - European Medical Journal

Understanding Adherence to Nutritional Therapy in Sickle Cell Anaemia

To investigate the feasibility of RUTF for children with SCA, the SAMS trial in Nigeria enrolled 108 children aged five to twelve with severe acute malnutrition.

Common Cold May Prime Children’s Defences Against COVID-19

A new study suggests that the common cold may boost children’s antiviral defences, lowering the risk and severity of COVID-19.

Study Finds mHealth App Reduces Hypertension, Especially in Women

A mobile health program significantly lowered blood pressure among users, with women—especially postmenopausal—showing greater improvements than men.

ESC 2025: Raising Potassium Reduces Ventricular Arrhythmia Risk in High-Risk Patients

The POTCAST trial shows raising plasma potassium to high-normal levels reduces ventricular arrhythmia risk, hospitalisations, and death in ICD patients.

New Treatment Shows Promise for Reducing Acne Scars

Objective biometric measures showed improvement in both groups, but the combination therapy produced significantly greater benefits.

ESC 2025: Digitoxin Trial Redefines Role of Glycosides in Heart Failure

DIGIT-HF shows digitoxin reduces death and hospitalisation in advanced heart failure, offering an additional option for high-risk patients on top of standard therapy.

ESC 2025: Age Drives Arrhythmia Risk While Fitness Offers Protection

A large study finds age strongly increases arrhythmia risk, while higher fitness levels protect against atrial ectopy in asymptomatic adults.

Can a New Biomarker Improve Bladder Cancer Detection?

With limited early-detection tools and only modest improvements in survival for advanced disease, clinicians urgently need reliable biomarkers to improve prognostication.

Airway Bacteria Show Protective Effect in Pneumonia and Flu

Airway bacteria like Streptococcus oralis may boost natural immune defences, helping protect against pneumonia and viral infections, new research suggests.

CML Study Reveals Transcript Type Influences Imatinib Effectiveness

A study finds that CML patients with the e13a2 BCR-ABL1 transcript show poorer molecular responses to imatinib compared to those with e14a2, suggesting transcript type may influence treatment outcomes.